Curis, Inc. (CRIS) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to QRIS's fourth quarter 2024 business update call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star key followed by zero. After the company's prepared remarks, call participants will have an opportunity to ask questions. To ask a question, you may press star, then the number one on your touchstone phone. To withdraw your question, please press star, then the number two. Please note this event is being recorded. I would now like to turn the conference over to Deonta Duvall, Curis' Chief Financial Officer. Deonta, please go ahead. Thank you, and welcome to Curis' fourth quarter 2024 business update call. Before we begin, I would like to encourage everyone to go to the investor section of our website at www.curis.com to find our fourth quarter 2024 business update press release, and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me on today's call are Jim Denser, President and Chief Executive Officer, and Jonathan Zone, Chief Development Officer. We will also be available for a question and answers period at the end of the call. I'd now like to turn the call over to Jim. Thank you, Diantha. Good morning, everyone, and welcome to Kyrus' fourth quarter business update call. We made great progress this quarter in both NHL and AML. Let's start with our take-game lymphoma study, which is evaluating M of Usertib in combination with Ibrutinib in PCNSL. Before we discuss ...